Platelet contributions to the pathogenesis of systemic sclerosis

Current Opinion in Rheumatology

Volumn 19, Issue 6, 2007, Pages 574-579

  Postlethwaite, Arnold E ^a,b   Chiang, Thomas M ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Phosphilidylinositol 3 kinase; Platelets; Systemic sclerosis; Type I collagen

Indexed keywords

CHEMOKINE; COLLAGEN RECEPTOR; COLLAGEN TYPE 1; CYTOKINE; GROWTH FACTOR; ILOPROST; INTEGRIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE;

AUTOIMMUNITY; CYTOKINE RELEASE; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; LUNG FIBROSIS; MOLECULAR WEIGHT; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SYSTEMIC SCLEROSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANIMALS; AUTOANTIGENS; BLOOD PLATELETS; HUMANS; PLATELET ACTIVATION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 34948844518     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282eeb3a4     Document Type: Review

References (47)

1. Italino JE, Hartwig J. Megakaryocyte development and platelet formation. In: Michelson AD, editor. Platelets. San Diego: Academic Press; 2002. pp. 21-35.
2. O'Sullivan BP, Michelson AD. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med 2006; 173:483-490. •• This paper is a comprehensive review of the dysregulated platelet function in cystic fibrosis and asthma. Platelet biology is reviewed.
3. Miller K, Dresner IG, Michael AF. Localization of platelet antigens in human kidney disease. Kidney Int 1980; 18:472-479.
4. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998; 12:1035-1044.
5. Klinger M. Inflammation. In: Michelson AD, editor. Platelets. San Diego: Academic Press; 2002. pp. 459-467.
6. Kahaleh MB, Osborn I, Leroy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982; 96:610-613.
7. Cuenca R, Fernandez-Cortijo J, Lima J, et al. Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma. Med Clin (Barc) 1990; 95:761-763.
8. Belch JJ, O'Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1985; 24:346-350.
9. Biondi ML, Marasini B, Bianchi E, Agostoni A. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Int J Cardiol 1988; 19:335-339.
10. Klimiuk PS, Grennan A, Weinkove C, Jayson MI. Platelet serotonin in systemic sclerosis. Ann Rheum Dis 1989; 48:586-589.
11. Mannucci PM, Lombardi R, Lattuada A, et al. Supranormal von Willebrand factor multimers in scleroderma. Blood 1989; 73:1586-1591.
12. Friedhoff LT, Seibold JR, Kim HC, Simester KS. Serotonin induced platelet aggregation in systemic sclerosis. Clin Exp Rheumatol 1984; 2:119-123.
13. Czirjak L, Molnar I, Csipo I, et al. Antiplatelet antibodies against gpIIb/IIIa in systemic sclerosis. Clin Exp Rheumatol 1994; 12:527-529.
14. Silveri F, De Angelis R, Poggi A, et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001; 30:290-296.
15. Massabki PS, Silva NP, Lourenco DM, Andrade LE. Neuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis. J Rheumatol 2003; 30:2606-2612.
16. Kowal-Bielecka O, Kowal K, Lewszuk A, et al. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005; 64:484-486.
17. Chiang TM, Jin A, Hasty KA, Kang AH. Collagen-platelet interaction: inhibition by a monoclonal antibody which binds a 90,000 Dalton platelet glycoprotein. Thromb Res 1989; 53:129-143.
18. Tandon NN, Kralisz U, Jamieson GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 1989; 264:7576-7583.
19. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84:1440-1445.
20. Staatz WD, Rajpara SM, Wayner EA, et al. The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mgpp-dependent adhesion of platelets to collagen. J Cell Biol 1989; 108:1917-1924.
21. Chiang TM, Rinaldy A, Kang AH. Cloning, characterization, and functional studies of a nonintegrin platelet receptor for type I collagen. J Clin Invest 1997; 100:514-521.
22. Chiang TM. Collagen-platelet interaction: platelet nonintegrin receptors. Histol Histopathol 1999; 14:579-585.
23. Chiang TM, Kang AH. A synthetic peptide derived from the sequence of a type I collagen receptor inhibits type I collagen-mediated platelet aggregation. J Clin Invest 1997; 100:2079-2084.
24. Chiang TM, Cole F, Woo-Rasberry V. Cloning, characterization, and functional studies of a 47-kDa platelet receptor for type III collagen. J Biol Chem 2002; 277:34896-34901.
25. Zhu J, Cole F, Woo-Rasberry V, et al. Type I and type III collagen-platelet interaction: inhibition by type specific receptor peptides. Thromb Res 2007; 119:111-119. •• This paper describes novel synthetic peptide patterend after 65 kDa CI and 47 kDa CIII receptors and their ability to inhibit CI and CIII-induced platelet aggregation.
26. Puett D, Wasserman BK, Ford JD, Cunningham LW. Collagen-mediated platelet aggregation: effects of collagen modification involving the protein and carbohydrate moieties. J Clin Invest 1973; 52:2495-2506.
27. Brass LF, Bensusan HB. The role of collagen quaternary structure in the platelet: collagen interaction. J Clin Invest 1974; 54:1480-1487.
28. Chiang TM, Beachey EH, Kang AH. Interaction of a chick skin collagen fragment (alpha1-CB5) with human platelets: biochemical studies during the aggregation and release reaction. J Biol Chem 1975; 250:6916-6922.
29. Balleisen L, Marx R, Kuhn K. Platelet-collagen interaction: the influence of native and modified collagen (type I) on the aggregation of human platelets. Haemostasis 1976; 5:155-164.
30. Chiang TM, Mainardi CL, Seyer JM, Kang AH. Collagen-platelet interaction: type V (A-B) collagen induced platelet aggregation. J Lab Clin Med 1980; 95:99-107.
31. Chiang TM, Cremer M, Kang AH. Collagen-platelet interaction: type XI collagen-induced platelet aggregation. Thromb Res 1990; 59:509-520.
32. Tryggvason K, Oikarinen J, Viinikka L, Ylikorkala O. Effects of laminin, proteoglycan and type IV collagen, components of basement membranes, on platelet aggregation. Biochem Biophys Res Commun 1981; 100:233-239.
33. Chiang TM, Takayama H, Postlethwaite AE. Increase in platelet nonintegrin type I collagen receptor in patients with systemic sclerosis. Thromb Res 2006; 117:299-306. •• This paper is the first to characterize an overexpressed receptor or platelet for CI. Other integrin and nonintegrin receptors and the 47 kDa CIII receptor were not overexpressed.
34. Chiang TM, Cole F, Woo-Rasberry V, Kang ES. Role of nitric oxide synthase in collagen-platelet interaction: involvement of platelet nonintegrin collagen receptor nitrotyrosylation. Thromb Res 2001; 102:343-352.
35. Hartwig JH, Kung S, Kovacsovics T, et al. D3 phosphoinositides and outside- in integrin signaling by glycoprotein IIb-IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12-myristate 13-acetate. J Biol Chem 1996; 271:32986-32993.
36. Rosado JA, Sage SO. Phosphoinositides are required for store-mediated calcium entry in human platelets. J Biol Chem 2000; 275:9110-9113.
37. Way BA, Mooney RA. Activation of phosphatidylinositol-3-kinase by platelet-derived growth factor and insulin-like growth factor-1 is inhibited by a transmembrane phosphotyrosine phosphatase. J Biol Chem 1993; 268:26409-26415.
38. Deora AA, Win T, Vanhaesebroeck B, Lander HM. A redox-triggered ras-effector interaction: recruitment of phosphatidylinositol 3′-kinase to Ras by redox stress. J Biol Chem 1998; 273:29923-29928.
39. Chiang TM, Postlethwaite AE. Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis. Biochim Biophys Acta 2006; 1760:32-37. •• This paper demonstrates that PI 3-K activity is constitutively increased in SSc platelets by posttranslational modification by nitrotyrosylation. The increased PI 3-K nitrotyrosylation may contribute to increased platelet reactivity to matrix components such as CI.
40. Stojanovic A, Marjanovic JA, Brovkovych VM, et al. A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. J Biol Chem 2006; 281:16333-16339. • This paper describes how PI 3-K/Akt are involved in platelet signaling important in aggregation and secretion of platelet contents.
41. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11:507-514.
42. Cosemans JM, Munnix IC, Wetzker R, et al. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 2006; 108:3045-3052.
43. Chiang TM, Postlethwaite AE. A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim Biophys Acta 2007; 1770:1181-1186. •• This paper describes the MEG-01 megakaryocyte line cultures with SSc CI-stimulated PBMC culture supernatants to generate overexpression of PI 3-K and Akt on the megakaryocyte. This report provides a possible link between T-cell autoimmunity and SSc platelet overexpression of PI 3-K, Akt and 65 kDa CI receptor.
44. Schluter H, Grobeta I, Bachmann J, et al. Adenosine(5′) oligophospho-(5′) guanosines and guanosine(5′) oligophospho- (5′) guanosines in human platelets. J Clin Invest 1998; 101:682-688.
45. Lefer AM, Smith EF 3rd, Araki H, et al. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA 1980; 77:1706-1710.
46. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54:1961-1973.
47. Fontana V, Horstman LL, Donna E, et al. Interstitial lung disease (ILD) and severe ITP. Hematology 2007; 12:75-80. •• This paper describes three patients with refractory ITP who developed interstitial lung disease, one which went on to develop advanced pulmonary fibrosis. Is this an experiment in nature proving platelet lysis in vivo leads to inflammatory and fibrotic consequences?